Latest Conference Articles

Kristine Kucera, PA-C, MPAS, DHS, reflects on her impactful 30-year career and celebrates the evolution of dermatology PAs at the SDPA Fall 2025 conference.

SDPA Emerging Scholars share insights on mentorship and professional growth, highlighting the importance of collaboration in dermatology.

Catch up on coverage from the first day of the 2025 SDPA Fall Conference held in San Antonio, Texas.

Amanda Mixon, PA-C, highlights critical cutaneous signs of connective tissue diseases at SDPA 2025, enhancing early diagnosis and treatment strategies.

Yasmine Kirkorian, MD, shares insights on pediatric dermatology advancements and genetic skin disorders at SDPA Fall 2025, emphasizing early diagnosis and innovative therapies.

Discover the latest in skin health innovations and skin care trends shared at SDPA Fall 2025, featuring insights from Heather C. Woolery-Lloyd, MD, FAAD.

Explore insights from SDPA leaders Renata Block, DMSc, MMS, PA-C, and Sarah Vicari, MMS, PA-C, on mentorship, volunteerism, and fostering growth for PAs.

What exciting sessions and updates are you looking forward to at the SDPA Fall 2025 Conference in San Antonio? Click here to answer our poll and let us know!

Preview the SDPA Fall 2025 conference in San Antonio for 4 days of networking, education, and expert-led sessions for dermatology PAs.

New findings from LEO Pharma reveal chronic hand eczema affects 1 in 10 adults, highlighting the need for improved recognition and management in dermatology.

Advances in atopic dermatitis research could bring longer-lasting biologics and improved treatment adherence.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Pennsylvania Dermatology Physician Assistants (PDPA) Keystone Dermatology Conference in Philadelphia, Pennsylvania.

At Fall Clinical 2025, Andrew Alexis, MD, reviewed topical, oral, and procedural interventions with patients with melasma and hyperpigmentation, especially in patients with skin of color.

Catch up on coverage from the entire 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.

Join leading experts at the 2025 Inflammatory Skin Disease Summit to explore groundbreaking research and innovations in dermatologic care and therapies.

According to a poster at Fall Clinical 2025, over 80% of patients remained flare-free across the 2-year period.

At Fall Clinical, new findings from the ENCOMPASS study revealed significant unmet needs in psoriasis care, highlighting a strong preference for effective oral therapies among patients and providers.

Catch up on coverage from the last day of the 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.

At Fall Clinical 2025, Mona Shahriari, MD, presented highlights on the role of IL-13 inhibitors, such as dupilumab, tralokinumab, and lebrikizumab, in managing atopic dermatitis across severities.

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

At Fall Clinical 2025, Ron Vender, MD, discussed the evolving psoriasis treatment landscape and the persistent challenge of managing palmoplantar pustulosis.

Gene expression profiling may allow clinicians, according to Farberg, to predict patient responses to targeted treatments.

Peter Lio, MD, believes that collaboration between science and industry is vital for translating research into meaningful patient benefits.

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

Catch up on coverage from the third day of the 2025 Fall Clinical Dermatology Conference held in Las Vegas, Nevada.

Clinicians are now aiming for treatment targets such as NRS 0–1, IGA 0–1, and EASI 90 to define successful AD management.

At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”